Dose-finding study of peginesatide for anemia correction in chronic kidney disease patients.

ABSTRACT:

Background and objectives

Peginesatide is a synthetic, PEGylated, investigational, peptide-based erythropoiesis-stimulating agent. We report the first assessment of its efficacy and safety in correcting renal anemia in a population of 139 nondialysis chronic kidney disease patients.

Design, setting, participants, & measurements

Chronic kidney disease patients who were not on dialysis and not receiving treatment with erythropoiesis-stimulating agents in the 12 weeks before study drug administration were sequentially assigned to one of 10 cohorts; cohorts differed in starting peginesatide dose (different body weight-based or absolute doses), route of administration (intravenous or subcutaneous), and frequency of administration (every 4 or 2 weeks).

Results

Across all co

SUBMITTER: Macdougall IC 

PROVIDER: S-EPMC3359570 | biostudies-literature | 2011 Nov

REPOSITORIES: biostudies-literature